Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection

Int J Hematol. 2023 Dec;118(6):772-775. doi: 10.1007/s12185-023-03649-0. Epub 2023 Aug 14.

Abstract

A 45-year-old man who was a sibling donor for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was administered 7.2 mg of pegfilgrastim for stem cell collection. Peripheral blood stem cells were collected 4 days after administration of pegfilgrastim (Day 4) and 4.32 × 106 /kg of CD34-positive cells per recipient body weight were obtained. Fever of 38 ℃ or higher and left submandibular pain appeared on Day 6. Ultrasonography and contrast-enhanced computed tomography (CT) showed wall thickening of the carotid artery and the abdominal aorta. We carefully excluded the possibilities of cardiovascular and autoimmune diseases by thorough examination, and ultimately diagnosed pegfilgrastim-induced aortitis. The patient's fever resolved rapidly after treatment with prednisolone (PSL) 1 mg/kg. We began to taper PSL after eight days. Sixty-one days after starting PSL, we confirmed that abdominal aortic wall thickening had improved by contrast-enhanced CT. We continued to taper off PSL and stopped 141 days later with no relapse thereafter. This is the first case report of pegfilgrastim-induced aortitis in an allo-PBSCT donor. Careful monitoring is warranted when administering pegfilgrastim to donors even without past medical history.

Keywords: Allogeneic peripheral blood stem cell transplantation; Aortitis; Donor; Pegfilgrastim.

Publication types

  • Case Reports

MeSH terms

  • Aortitis* / chemically induced
  • Aortitis* / therapy
  • Filgrastim / adverse effects
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cells*

Substances

  • pegfilgrastim
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim